◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Apogee Therapeutics, Inc. Common Stock (APGE) EBITDA 2022–TTM

Name: Apogee Therapeutics, Inc. Common Stock (APGE) ebitda history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-07-30

Apogee Therapeutics, Inc. Common Stock annual ebitda for fiscal TTM was -$273 million, a decrease of 7.5% from -$254 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

APGE Annual EBITDA

EBITDA (annual)	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31
EBITDA	($273M)	($254M)	($182M)	($75M)	($40M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

APGE Quarterly EBITDA

EBITDA (quarterly)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
EBITDA	($74M)	($69M)	($65M)	($66M)	($55M)	($67M)	($49M)	($34M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

AXSM EBITDA — Axsome Therapeutics Inc
SMMT EBITDA — Summit Therapeutics PLC
CYTK EBITDA — Cytokinetics Inc
PRAX EBITDA — Praxis Precision Medicines Inc
PTGX EBITDA — Protagonist Therapeutics Inc
KRYS EBITDA — Krystal Biotech Inc

More APGE metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All APGE financial statements → Interactive APGE charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.